Moderna's stock surged +10.85% after the company filed for global regulatory approval of its promising mRNA-1010 seasonal flu vaccine, boosting investor confidence in its strategic pivot toward a diversified respiratory vaccine portfolio.
- The company announced it exceeded its 2025 cost-reduction targets by nearly $1 billion.
- Management is now targeting cash breakeven by 2028.
- The positive momentum was reinforced after Bank of America Securities raised Moderna's price target.